Arrivent Biopharma, INC 8-K filings

ArriVent BioPharma announced a material definitive agreement to license ARR-002 to Allist Pharmaceuticals for Greater China, alongside reporting Q2 2026 financial results and pipeline updates.

ArriVent BioPharma announces a $250 million at-the-market offering program through a prospectus supplement filed on May 11, 2026.

ArriVent BioPharma reported Q1 2026 results, highlighting clinical advancements for firmonertinib and ARR-002, with cash reserves projected to fund operations into late 2027.

ArriVent BioPharma announced plans to present two preclinical posters on its EGFR inhibitor firmonertinib and novel dual-target ADC ARR-002 at the 2026 AACR Annual Meeting.

ArriVent BioPharma announced its full-year 2025 financial results, reporting a significant increase in net loss and R&D expenses, while highlighting key clinical advancements and a cash runway into Q3 2027.

ArriVent BioPharma announced its third quarter 2025 financial results, highlighting significant clinical progress for firmonertinib in NSCLC and its ADC pipeline, alongside a strong cash position.

ArriVent BioPharma presented positive final data from its global Phase 1b study of firmonertinib monotherapy in EGFR PACC mutant non-small cell lung cancer.

ArriVent BioPharma reported second quarter 2025 financial results, highlighted positive interim Phase 1b firmonertinib data, and announced progress in its ADC pipeline.

ArriVent BioPharma, Inc. announced that topline data from its pivotal Phase 3 FURVENT study of firmonertinib for first-line EGFR exon20 insertion mutant non-small cell lung cancer is projected to be available in early 2026.

ArriVent BioPharma, Inc. announced the pricing of an underwritten public offering expected to generate approximately $75 million in gross proceeds through the sale of common stock and pre-funded warrants.

ArriVent BioPharma, Inc. announced positive interim data from its global Phase 1b study of firmonertinib monotherapy in EGFR PACC mutant non-small cell lung cancer, leading to plans for a global pivotal Phase 3 study.

ArriVent BioPharma, Inc. successfully held its 2025 annual meeting of stockholders, electing two Class I directors and ratifying PricewaterhouseCoopers LLP as its independent accounting firm.

ArriVent BioPharma announces its first quarter 2025 financial results, highlighting the completion of enrollment in a pivotal Phase 3 study for firmonertinib and the submission of an IND for ARR-217 in China.

ArriVent BioPharma appoints Merdad Parsey, former Chief Medical Officer of Gilead Sciences, to its Board of Directors, effective April 28, 2025.

ArriVent BioPharma has dismissed KPMG as its independent auditor and appointed PricewaterhouseCoopers (PwC) in its place, effective March 11, 2025.

ArriVent BioPharma announces its full year 2024 financial results, showcasing progress in firmonertinib clinical programs and expansion of its ADC portfolio.

ArriVent BioPharma secures exclusive rights to develop and commercialize MRG007, a promising antibody drug conjugate for gastrointestinal cancers, outside of Greater China, through a licensing agreement with Lepu Biopharma.

ArriVent BioPharma reported its third quarter 2024 financial results, highlighting progress in its firmonertinib clinical program and a strong cash position.

ArriVent BioPharma reported positive interim results from a Phase 1b trial of firmonertinib, showing promising activity against EGFR PACC mutant non-small cell lung cancer.

ArriVent BioPharma reported its second quarter 2024 financial results, highlighted by advancements in its oncology pipeline, including upcoming presentation of clinical data for firmonertinib.

ArriVent BioPharma has amended its previous filing to announce the appointment of Dr. John Hohneker to the Nominating and Corporate Governance Committee and Compensation Committee, effective immediately on July 3, 2024.

ArriVent BioPharma has appointed Kristine Peterson, a seasoned biopharmaceutical executive, to its Board of Directors, effective immediately.

ArriVent BioPharma has entered into a collaboration with Alphamab to develop and commercialize novel antibody drug conjugates (ADCs) for cancer treatment, with potential milestone payments reaching $615.5 million.

ArriVent BioPharma has appointed John Hohneker, M.D., a seasoned biopharmaceutical executive, to its Board of Directors, effective May 16, 2024.

ArriVent BioPharma announced its first quarter 2024 financial results, highlighting clinical advancements including the dosing of the first patient in a Phase 1b combination study and presentation of preclinical data.

ArriVent BioPharma has appointed Kristine Peterson, a seasoned biopharmaceutical executive, to its Board of Directors, effective immediately.

ArriVent BioPharma announced its full year 2023 financial results, highlighted clinical progress with furmonertinib, and reported a successful $201 million IPO.

ArriVent BioPharma successfully closed its IPO, raising $175 million, and concurrently amended its certificate of incorporation and bylaws.